Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. The disease can be treated by surgical methods that involve removal of the tumour. A combination of chemotherapy and radiation therapy is also required for further destruction of cancer cells. Ziopharm Oncology, Inc. is in the process of developing INXN-2001 as a gene therapy for the treatment of anaplastic oligoastrocytoma. The Sun Yat-sen University is in the process of developing β-elemene as an anti-tumour agent for the treatment of anaplastic oligoastrocytoma. Some of the companies and universities having the pipeline of anaplastic oligoastrocytoma include Novartis AG, Northwestern University, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.